

Please try another search
By Sam Boughedda
Investing.com — Moderna Inc (NASDAQ:MRNA) shares fell Wednesday after the company lost an appeal on a patent ruling involving Arbutus Biopharma Corp (NASDAQ:ABUS).
The U.S. Court of Appeals for the Federal Circuit affirmed the Appeals Board and Patent Trial decisions regarding two Arbutus patents concerning drug-delivery technology. Accordingly, the court dismissed Moderna's appeal for "lack of standing." The decision, which upholds last year's ruling, means Moderna could now face a patent infringement lawsuit.
Moderna shares are down over 8.6%, while Arbutus shares have almost doubled, currently up 90%.
One of the two patents involved is the 435 patent, which is shown to "stable nucleic acid-lipid particles comprising a nucleic acid, methods of making SNALP, and methods of delivering and/or administering the SNALP."
Moderna has previously said that if the claims were upheld, Arbutus could use a lawsuit to demand royalties for the Moderna Covid-19 vaccine.
By Ludwig Burger and Christoph Steitz FRANKFURT (Reuters) -Siemens Energy on Saturday said it would offer 18.05 euros ($19.06) per share for the remaining third it does not...
(Reuters) - The first shipments of infant formula from Europe to address a critical shortage in the United States should begin arriving this weekend, President Joe Biden said on...
(Reuters) - HSBC Holdings (NYSE:HSBC) CEO Noel Quinn says his bank will not be distracted from its ambition to lead the global economy in the transition to net zero, after a...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.